Earnings Surprise: Recent chatter on X about Pfizer Inc. (PFE) has focused on the company’s latest quarterly earnings, which beat earnings per share expectations but missed revenue forecasts. Many are intrigued by the raised profit guidance despite declining sales figures. The discussion highlights a mix of optimism and concern over future growth.
Strategic Moves: Posts on X also point to Pfizer’s strategic plans, including a significant $70 billion investment in U.S. manufacturing and ongoing biotech acquisitions. Some see this as a bold play to reposition the company amid a shifting pharmaceutical landscape. It’s a topic sparking curiosity about long-term impacts on the stock.
Stock Performance: Conversations note Pfizer’s stock hovering near key resistance levels after a modest uptick, with some expressing frustration over its inability to gain stronger momentum. The stock’s recent dip of nearly 5% over the past month adds fuel to debates about its near-term direction. Investors seem to be watching closely for a potential breakout.
Note: This discussion summary was generated from an AI condensation of post data.
Pfizer Inc. Congressional Stock Trading
Members of Congress have traded $PFE stock 7 times in the past 6 months. Of those trades, 3 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 05/30 and 1 sale worth up to $15,000 on 08/05.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 07/16 and 1 sale worth up to $15,000 on 08/04.
- SENATOR RON WYDEN sold up to $15,000 on 06/03.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 06/03.
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $50,000 on 05/15.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Pfizer Inc. Hedge Fund Activity
We have seen 1,314 institutional investors add shares of Pfizer Inc. stock to their portfolio, and 1,462 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 26,490,160 shares (-25.6%) from their portfolio in Q2 2025, for an estimated $642,121,478
- BLACKROCK, INC. added 20,709,704 shares (+4.4%) to their portfolio in Q2 2025, for an estimated $502,003,224
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 17,885,662 shares (-23.7%) from their portfolio in Q3 2025, for an estimated $455,726,667
- AMUNDI removed 14,642,887 shares (-28.1%) from their portfolio in Q2 2025, for an estimated $354,943,580
- MARSHALL WACE, LLP removed 13,641,127 shares (-96.8%) from their portfolio in Q2 2025, for an estimated $330,660,918
- CAPITAL WORLD INVESTORS removed 13,368,274 shares (-49.1%) from their portfolio in Q2 2025, for an estimated $324,046,961
- QUBE RESEARCH & TECHNOLOGIES LTD removed 10,711,578 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $259,648,650
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Pfizer Inc. Government Contracts
We have seen $1,715,709 of award payments to $PFE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- STERILE WATER FOR INJECTION 20ML: $1,167,976
- PFIZER VACCINES STORAGE AND ROTATION CONTRACT: $410,203
- 4567359319!NALOXONE 4 MG/10 ML VIAL 10ML: $59,220
- 4568572944!NALOXONE 4 MG/10 ML VIAL 10ML: $11,280
- 4568676827!HEXTEND 6%-LACT ELEC BAG 500ML: $11,164
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Pfizer Inc. Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 3 analysts offer price targets for $PFE in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $32.0 on 10/10/2025
- Tim Anderson from B of A Securities set a target price of $30.0 on 10/03/2025
- Andrew Baum from Citigroup set a target price of $26.0 on 08/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
